Myelogenous Leukemia
📧 Sign up to get email alerts when something new happens for Myelogenous Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: INCB018424 in Patients With Advanced Hematologic Malignancies [Phase 2]
Phase 2 trial of INCB018424 (ruxolitinib) in patients with advanced hematologic malignancies. Results for diseases including AML, ALL, MDS, …
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) [Phase 2]
Phase 2 trial update for ponatinib in chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia has complet…
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases [NA]
Clinical trial update for reduced intensity conditioning and haploidentical related bone marrow transplant in hematologic diseases; the stud…
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant [Phase 2]
Phase 2 trial investigating sirolimus, cyclosporine, and mycophenolate mofetil to prevent graft-versus-host disease in patients with blood c…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-08-12Clinical Trial Update: Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial comparing polyethylene glycol interferon alfa-2b (PEG Intron) to interferon alfa-2b (INTRON A) for newly diagnosed c…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation [Phase 2]
Phase 2 pilot trial evaluating leuprolide to enhance immune function after allogeneic bone marrow transplantation has completed and results …
-
CLINICAL_TRIALS trial_result · 2019-03-05Clinical Trial Update: Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention [NA]
A completed clinical trial evaluating a cognitive behavioral intervention for fatigue in patients undergoing targeted therapy for chronic my…
-
CLINICAL_TRIALS trial_result · 2018-11-02Clinical Trial Update: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 trial investigating sequences of dasatinib or nilotinib followed by imatinib in newly diagnosed chronic phase chronic myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2018-08-29Clinical Trial Update: Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI [Phase 1, Phase 2]
Phase 1/2 clinical trial update for Philadelphia chromosome–positive CML patients with suboptimal response or tolerance to Bcr-Abl TKIs.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Improving Blood Stem Cell Collection and Transplant Procedures [Phase 1, Phase 2]
Phase 1/2 clinical trial update focused on improving blood stem cell collection and transplant procedures, completed with results reported b…
-
CLINICAL_TRIALS trial_result · 2018-04-25Clinical Trial Update: Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation [Phase 1, Phase 2]
A phase 1/2 trial of Clofarabine combined with non-myeloablative allogeneic hematopoietic transplantation was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2017-11-29Clinical Trial Update: Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia [Phase 2]
This is a Phase 2 trial of cyclophosphamide and filgrastim followed by stem cell transplantation in patients with chronic myelogenous leukem…
-
CLINICAL_TRIALS research · 2017-08-10Clinical Trial Update: Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel
A completed Israeli clinical trial analyzing genetic factors associated with predisposition and prognosis of hematologic malignancies, inclu…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating fludarabine phosphate, melphalan, and low-dose total-body irradiation followed by donor peripheral blood stem cell …
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NA]
Clinical trial update for fludarabine-based conditioning prior to allogeneic transplantation in advanced hematologic malignancies; study com…
-
CLINICAL_TRIALS trial_result · 2017-05-12Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of HSC835 in patients with various hematologic malignancies completed with results posted …
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs [Phase 2]
A Phase 2 safety and tolerability trial evaluating CDX-301 with or without plerixafor for stem cell mobilization in matched related donor/re…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating therapeutic allogeneic lymphocytes with aldesleukin for high-risk or recur…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment [Phase 2]
This document reports the completion of a Phase 2 clinical trial evaluating sargramostim for patients with chronic phase chronic myeloid leu…
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies [Phase 2, Phase 3]
This clinical trial update reports results from a study of continued treatment with peginterferon alfa-2a or recombinant interferon alfa-2a …
-
CLINICAL_TRIALS trial_result · 2016-08-04Clinical Trial Update: Sitagliptin Umbilical Cord Blood Transplant Study [Phase 2]
Phase 2 clinical trial update on sitagliptin in the setting of umbilical cord blood transplantation, with results posted in 2016 for several…
-
EMA approval · 2016-04-29New treatment for rare white blood cell cancer
The EMA announces a new treatment for a rare white blood cell cancer, representing a targeted option for this rare indication.
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 trial testing belinostat and bortezomib in relapsed or refractory acute leukemias and myelodysplastic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer [Phase 2]
Phase 2 trial update of Basiliximab to prevent graft-versus-host disease after nonmyeloablative allogeneic transplantation in blood cancers;…